

RELEASE – UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Unaudited consolidated interim financial statements for the half year ended 30<sup>th</sup> September 2019

Zug, 30<sup>th</sup> January 2020

**Unaudited consolidated interim income statement**

**Total Revenue**

Consolidated Total Revenue for the first half of the financial year 2019-20 (H1FY20) was at USD 157.73 million, a decrease of 6.1% over the same period in prior year 2018-19 (H1FY19).

**Gross Margin**

The Gross Margin ratio were at 55.2% during the first half of the financial year 2019-20 (H1FY20), compared to 50.0% over the same period in prior year 2018-19 (H1FY19).

**Operating Income**

The Operating Income for the first half of the financial year 2019-20 (H1FY20) was at USD 6.35 million, compared to Operating Loss of USD 6.08 million over the same period in prior year 2018-19 (H1FY19).

**Profit/Loss**

The Loss for the first half of the financial year 2019-20 (H1FY20) was USD 4.23 million, compared to a Loss of USD 18.41 million over the same period in prior year 2018-19 (H1FY19).

**Unaudited consolidated interim balance sheet**

**Balance sheet to 30<sup>th</sup> September 2019 with reference to prior year's result ended 31<sup>st</sup> March 2019**

The Net Debt to Equity ratio as at 30<sup>th</sup> September 2019 stands at 0.72 compared to 0.83 as at 31<sup>st</sup> March 2019.

Cash and cash equivalents and Securities stands at USD 15.36 million as on 30<sup>th</sup> September 2019, compared to USD 49.38 million as on 31<sup>st</sup> March 2019.

## Notes to the consolidated interim financial statements

### 1. Accounting policies

These consolidated interim financial statements include the unaudited consolidated interim financial statements of Wockhardt Bio AG and its subsidiaries for the reporting period ending September 30, 2019. The consolidated interim financial statements have been prepared in accordance with Swiss GAAP FER 31 "Interim Reporting". The consolidated interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual consolidated financial statements as at March 31, 2019. The accounting policies applied to the preparation of the interim financial statements are in line with the accounting policies which also provide the basis for the consolidated annual financial statements up to March 31, 2019. The Group has adopted Swiss GAAP FER 31 with effect of April 1, 2015. The new rules had no impact on the consolidated interim balance sheet and income statement of the Group. The consolidated interim financial statements were approved for issue by the Board of Directors on January 29, 2020.

Wockhardt Bio AG is not exposed to significant seasonal or cyclical fluctuation in its business activities within the financial year. In order to prepare consolidated interim financial statements, management is obliged to use estimates and assumptions which have an impact on the reported carrying amounts of assets and liabilities, and the income and expenses reported for the relevant accounting period. These estimates and assumptions are based on future expectations, and seem reasonable at the time of preparation of the interim financial statements. The actual results may differ from these assumptions.

### 2. Previous year figures

The consolidated interim income statement and the consolidated interim cash flow statement were compared with the period April 1, 2018 to September 30, 2018, while the consolidated interim balance sheet and the consolidated interim changes in equity were compared with March 31, 2019.

---

## Stock Listing

The registered shares of Wockhardt Bio AG are traded at the BX Bern eXchange.

Ticker Symbols:

WBIO (Telekurs)

Securities number 19304250

ISIN CH 019 304 250 1

Unaudited Consolidated Interim Income statement

in USD Mn	1.4.2019 - 30.9.2019	1.4.2018 - 30.9.2018
Net sales from goods and services	157,01	165,52
Other operating income	0,72	2,39
<b>Total revenue</b>	<b>157,73</b>	<b>167,91</b>
Change in inventory of finished and unfinished goods	(2,29)	4,65
Material expense	(68,29)	(88,65)
Personnel expense	(34,53)	(36,14)
Other operating expense	(41,95)	(49,04)
Depreciation on tangible fixed assets	(2,41)	(2,46)
Amortisation on intangible assets	(1,91)	(2,35)
<b>Total expenses</b>	<b>(151,38)</b>	<b>(173,99)</b>
<b>Operating result</b>	<b>6,35</b>	<b>(6,08)</b>
Financial income / (expenses)	(7,34)	(12,74)
<b>Ordinary result</b>	<b>(0,99)</b>	<b>(18,82)</b>
Income taxes	(3,24)	0,41
<b>Profit/(loss)</b>	<b>(4,23)</b>	<b>(18,41)</b>
<b>Basic and also diluted earnings per share (In USD):</b>		
Earnings per share	(0,08)	(0,35)

Unaudited Consolidated Interim balance sheet

in USD Mn	30.9.2019	30.9.2018
<b>Assets</b>		
Cash and cash equivalents	15,36	82,45
Securities	-	3,51
Receivables from goods and services	119,47	125,48
Other short-term receivables	6,95	0,48
Advance receivable - related party	95,05	99,43
Inventories	55,71	76,57
<b>Current assets</b>	<b>292,54</b>	<b>387,92</b>
Tangible assets	120,60	114,95
Intangible assets	175,30	148,56
Deferred income tax assets	20,00	27,49
<b>Non-current assets</b>	<b>315,90</b>	<b>291,00</b>
<b>Total assets</b>	<b>608,44</b>	<b>678,92</b>
<b>Liabilities and equity</b>		
Short-term financial liabilities	79,19	79,15
Payables from goods and services	160,19	120,10
Other short-term liabilities	25,43	40,41
Short-term provisions	10,68	14,53
Accrued liabilities and deferred income	0,17	0,73
<b>Current liabilities</b>	<b>275,66</b>	<b>254,92</b>
Long-term financial liabilities	99,75	179,94
Long-term provisions	-	-
Deferred income tax liabilities	7,12	9,01
<b>Non-current liabilities</b>	<b>106,87</b>	<b>188,95</b>
Share capital	56,21	56,21
Legal reserves	26,76	26,76
Capital reserve	60,54	60,54
Currency translation adjustments	(82,86)	(83,02)
Retained earnings	165,26	174,56
<b>Total equity</b>	<b>225,91</b>	<b>235,05</b>
<b>Total liabilities and equity</b>	<b>608,44</b>	<b>678,92</b>

Unaudited Consolidated cash flow statement

in USD Mn	1.4.2019 - 30.9.2019	1.4.2018 - 30.9.2018
Profit/(loss) for the year	(4,23)	(18,41)
+/- depreciation/amortisation of tangible/intangible assets	4,32	4,81
-/+ increase / decrease in value of securities	-	4,73
+/- increase / decrease of provisions (including deferred income taxes) that do not affect the fund	(0,84)	(0,01)
+/- decrease / increase of inventories	9,11	(0,54)
+/- decrease / increase of other receivables	(1,77)	6,55
+/- increase / decrease of receivables from deliveries and services	11,31	(18,23)
+/- increase / decrease of payables from goods and services	5,92	15,15
+/- increase / decrease of other short-term liabilities and accrued liabilities and deferred income	13,62	5,75
<b>Net cash flow from operating activities</b>	<b>37,44</b>	<b>(0,20)</b>
+/- inflows/outflows for investment (purchase) of tangible fixed assets	(3,41)	(5,33)
+/- inflows/outflows from disposal (selling)/purchase of financial assets (securities)	-	24,49
+/- outflows for investment (purchase) of intangible assets	(15,58)	(14,14)
+ inflows from disposal (selling) of tangible/intangible assets	1,36	-
<b>Net cash flow from investing activities</b>	<b>(17,63)</b>	<b>5,02</b>
+/- issuance / repayment of short-term financial liabilities	(17,91)	(26,26)
+/- issuance / repayment of long-term financial liabilities	(40,57)	(41,42)
<b>Net cash flow from financing activities</b>	<b>(58,48)</b>	<b>(67,68)</b>
<b>Net change in cash and cash equivalents</b>	<b>(38,67)</b>	<b>(62,86)</b>
Cash and cash equivalents at the beginning of the period	49,39	145,49
Net change in cash and cash equivalents	(38,67)	(62,86)
Exchange (losses) / gains on cash	4,64	(0,18)
<b>Cash and cash equivalents at the end of the period</b>	<b>15,36</b>	<b>82,45</b>



Unaudited Consolidated statement of changes in equity

in USD Mn

	Share capital	Legal Reserves	Capital reserve	Currency translation adjustments	Retained earnings	Total equity
Balance at April 1, 2018	56,21	26,76	60,54	(82,84)	192,97	253,63
Capital Increase						-
Share Premium						-
Profit/(loss)					(23,47)	(23,47)
Currency translation adjustments				(4,66)		(4,66)
Balance at March 31, 2019	56,21	26,76	60,54	(87,50)	169,50	225,50
Profit/(loss)					(4,23)	(4,23)
Currency translation adjustments				4,64		4,64
Balance at Sept. 30, 2019	56,21	26,76	60,54	(82,86)	165,27	225,91